VolitionRx Secures $2.0 Million in Funding

Core Viewpoint - VolitionRx Limited has entered into an amended agreement with Lind Global Asset Management to secure $2,000,000 in funding through the issuance of a senior secured convertible promissory note and a common stock purchase warrant, enhancing its financial position for future growth [1][2]. Group 1: Financial Details - The company will issue a senior secured convertible promissory note with a principal amount of $2,400,000 and a common stock purchase warrant to purchase up to 7,000,350 shares at an exercise price of $0.5714 per share [1]. - The 2026 Note will be repaid in eighteen monthly installments of $133,333 starting six months after issuance, with the option for the investor to increase payments up to $1,000,000 for two months [3]. - A commitment fee of $70,000 will be paid to the investor, deducted from the funding received [1]. Group 2: Previous Agreements - The amended agreement updates a previous securities purchase agreement from May 15, 2025, where the company issued a senior secured convertible promissory note of $7,500,000 and a warrant for 13,020,834 shares [2]. - Both the 2025 and 2026 Notes are secured by the assets of the company and its subsidiaries [2]. Group 3: Regulatory Compliance - The company is required to file a registration statement within 30 days of closing to cover the resale of shares issued upon conversion of the 2026 Note or exercise of the 2026 Warrant [4]. Group 4: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].